All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-03-05T09:57:54.000Z

What were your highlights from ASH 2023?

Mar 5, 2024
Share:

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. 

What were your highlights from ASH 2023?

Bar-Natan discusses recent data on menin inhibitors for the treatment of relapsed/refractory KMT2A-rearranged or NPM1-mutated acute myeloid leukemia. This includes trials assessing JNJ-75276617 monotherapy, revumenib monotherapy (AUGMENT-101 trial), revumenib in combination with decitabine and cedazuridine plus venetoclax, and ziftomenib in combination with either intensive chemotherapy or non-intensive chemotherapy in both relapsed/refractory and first-line settings. 

This interview is also available as a podcast here

Newsletter

Subscribe to get the best content related to AML delivered to your inbox